Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses-Reference-Cited by-同舟云学术

Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses

Published:2016-10 Issue: Volume:27 Page:vi329
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Brose M.,Jarzab B.,Elisei R.,Giannetta L.,Bastholt L.,Fouchardiere Cdela,Pacini F.,Paschke R.,Nutting C.,Shong Y.K.,Sherman S.,Smit J.,Chung J.,Meinhardt G.,Schlumberger M.,Kappeler C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/suppl_6/953PD/19450913/mdw376.06.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer;JCO Oncology Practice;2024-07

2. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer;Cancer Medicine;2022-10

3. Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects;Frontiers in Endocrinology;2022-07-08

4. Management of VEGFR-Targeted TKI for Thyroid Cancer;Cancers;2021-11-04

5. Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR;European Journal of Cancer;2021-11